NCT03950297: Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated unstable brain metastases- see trial for details; Patients with active autoimmune diseases or history of autoimmune diseases

Comments are closed.

Up ↑